Clinical trial
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary…
NCT00048776 · Otsuka America Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00048776 |
|---|---|
| Title | Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon |
| Lead sponsor | Otsuka America Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Raynaud's Disease |
| Intervention type | Drug |
| Interventions | Pletal |
| Enrollment | 75 |
| Start date | Oct 1, 2001 |
| Completion | Jun 1, 2003 |
| First posted | Nov 11, 2002 |
| Last update posted | Jul 19, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: